nature portfolio

Corresponding author(s):	Ron Weiss
Last updated by author(s):	April 5, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

<u> </u>			
St	at	ict	100

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	$oxed{x}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🕱 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
×	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
×	A description of all covariates tested
	🕱 A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
x	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
×	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
x	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
×	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

FACSDiva version 8.0.1 software was used to collect flow cytometry data. Data collection

Data analysis

Excel Version 16.40, Geneious Prime 2019.0.4, MATLAB 2019a. Custom MATLAB code was used for flow cytometry data analysis and plot generation and will be made available upon request.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Representative plasmid sequences have been deposited to Genbank with the accession codes OM256462-OM256466.

All plasmids used in this study are described in this paper and sequence information for parts are provided. Additional sequence information are available upon reasonable request from the authors. Raw .fcs files are available upon reasonable request. Source data are provided with this paper.

Field-spe	cific re	porting		
Please select the or	ne below that is	the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
x Life sciences	Be	ehavioural & social sciences		
For a reference copy of t	he document with a	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>		
Life scier	nces stu	ıdy design		
All studies must dis	close on these p	points even when the disclosure is negative.		
Sample size	No sample size of	calculations were performed. Sample sizes were chosen to align with what is typical in the field.		
Data exclusions		I, samples were excluded that contained fewer than 6 cells in order to ensure that summary values represented population responses. 2 cell line clones for each construct type, only up to 2 clones needed to be excluded. The threshold value of 6 cells was used for a CV		
Replication	All attempts at r	replication were successful and at least two independent experiments were performed at least two days apart.		
Randomization	single cell sortin were randomly	Most experiments were performed on immortalized cell lines, which were uniformly allocated to individual sample wells for transfection. For single cell sorting, an identical number of single cells were collected for each construct/treatment type. For the TetOn construct, plates of cells were randomly assigned to the treatment (+DOX) group or non-treatment (-DOX) group. 12 clones were picked randomly from each construct group for further evaluation.		
Blinding	_	nvestigators were not blinded to allocation during experiments due to limitations in personnel required to separately carry-out sample reparation and data collection.		
•		pecific materials, systems and methods		
		bout some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & exp	perimental sy	ystems Methods		
n/a Involved in th	e study	n/a Involved in the study		
* Antibodies		x ChIP-seq		
■ Image: Line state of the				
Palaeontology and archaeology MRI-based neuroimaging MRI-based neuroimaging				
Animals and other organisms Human research participants				
X Clinical data				
	search of concer	า		
—,—				
Eukaryotic ce	ell lines			
Policy information a	about <u>cell lines</u>			
Cell line source(s)	e(s) HEK-293FT cells: Thermo Fisher, CHO-K1 cells: ATCC			
Authentication None of the cell line		None of the cell lines were authenticated.		

All cell lines tested negative for mycoplasma.

None

Mycoplasma contamination

Commonly misidentified lines (See <u>ICLAC</u> register)

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- 🗶 All plots are contour plots with outliers or pseudocolor plots.
- 🗶 A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Cells were prepared for flow cytometry by trypsinization followed by re-suspension in FACS buffer.

Samples were collected on a BD LSR Fortessa.

FACSDiva version 8.0.1 software was used to collect flow cytometry data. Custom MATLAB code was used for analysis.

Cell population abundance

Sorted cells were single-cell sorted and therefore do not represent an abundance of the population. All construct types were sorted using the same copy number gate (EBFP) with the same mode. While, post-sort EBFP fluorescence was measured at each time point, we expected drifts in EBFP fluorescence due to epigenetic silencing thus this is not a purity metric.

Morphological gating was performed by gating on forward scatter (FSC) vs side scatter (SSC) area measurements to separate cells from debris, while additional gates on FSC and SSC height vs width measurements isolated singlet cells. Where it was necessary to gate untransfected cells from positively-transfected cells or highly-transfected cells, gate values are provided and example plots depicting gates are shown.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.